Dive Brief:
- Sanofi will give its business in China a more prominent billing in how it presents financial results, highlighting the growing importance of the country’s pharmaceutical market to the French drugmaker.
- In an organizational restructuring announced Thursday, two of Sanofi’s five “global business units” will be recast to more clearly split operations in mature economies like the U.S., Europe and Canada from emerging markets like China.
- The changes will rebrand Sanofi’s current general medicine and emerging markets unit as “China and Emerging Markets,” placing older, established products such as the company’s anticoagulant Lovenox alongside diabetes and cardiovascular medicines in a newly …
Read the full article at: https://www.biopharmadive.com/news/sanofi-looks-to-china-in-business-restructure/532335/